February 22, 2011
Cancer-Causing Virus Exploits Key Cell- Survival Proteins
A cancer-causing retrovirus exploits key proteins in its host cells to extend the life of those cells, thereby prolonging its own survival and ability to spread, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center "“ Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC "“ James) and Ohio State's College of Veterinary Medicine.
The human T-lymphotropic virus type-1 (HTLV-1), which causes adult T-cell leukemia and lymphoma, produces a protein called p30 that is essential for the retrovirus to establish an infection. This study found that this viral protein targets two important cell proteins: ATM, a key player in a cell's response to DNA damage, and REG-gamma, which marks proteins within the cell for destruction.
The findings were published recently in the Journal of Biological Chemistry.
An estimated 20 million people worldwide are infected by HTLV-1, and about five percent of them will develop adult T-cell leukemia or lymphoma, or one of a variety of inflammatory disorders.
Lairmore and his colleagues used cell lines and a variety of biochemical assays to identify cellular binding partners of p30. They discovered the following:
* p30 specifically binds to cellular ATM (ataxia-telangiectasia mutated), a key regulator of DNA damage responses and cell cycle control, and to REG-gamma, a nuclear proteasome activator.
* Under stressful conditions, p30 levels are associated with lower ATM levels and increased cell survival.
* The expression of p30 changes in concert with expression of REG-gamma, suggesting that overexpression of REG-gamma enhances levels of p30.
* p30 forms a complex with ATM and REG-gamma.
Funding from the National Cancer Institute supported this research.
Other Ohio State researchers involved in this study were Rajaneesh Anupam, Antara Datta, Matthew Kesic, Kari Green-Church, Nikolozi Shkriabai and Mamuka Kvaratskhelia.
The Ohio State University Comprehensive Cancer Center "“ Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (http://cancer.osu.edu) is one of only 40 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute. Ranked by U.S. News & World Report among the top cancer hospitals in the nation, The James is the 205-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC-James is one of only seven funded programs in the country approved by the NCI to conduct both Phase I and Phase II clinical trials.
On the Net: